Specific cyclooxygenase 2 inhibitors: A new choice of nonsteroidal anti- inflammatory drug therapy

Arthritis Care and Research

Volumn 12, Issue 5, 1999, Pages 351-362

  Osiri, Manathip ^a   Moreland, Larry W ^a,b  

^a University of Alabama at Birmingham   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; FLOSULIDE; FLURBIPROFEN; IBUPROFEN; IGURATIMOD; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIFLUMIC ACID; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; ROFECOXIB; SC 58135; SULINDAC; TENOXICAM; TOLFENAMIC ACID; UNCLASSIFIED DRUG;

ANALGESIA; ARTHRITIS; DRUG CHOICE; ENZYME INHIBITION; ENZYME SPECIFICITY; GASTROINTESTINAL TOXICITY; GENE LOCATION; HUMAN; HUMAN TISSUE; NEPHROTOXICITY; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW; THROMBOCYTE AGGREGATION;

EID: 0032737734     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199910)12:5<351::aid-art7>3.0.co;2-l     Document Type: Review

References (134)

1. Nishihara KK, Furst DE. Aspirin and other nonsteroidal anti-inflammatory drugs. In: Koopman WJ. editor. Arthritis and allied conditions. 13th ed. Baltimore: Williams & Wilkins; 1997. p. 611-54.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971;231:232-5.
3. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenaso homologue. J Biol Chem 1991;266:12866-72.
4. Xie WL, Chipman JG, Robutson DL, Erikson RL. Simmons DL. Expression of a mitogen-responsivo gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A 1991;88: 2692-6.
5. Smith TJ. Cyclooxygenases as the principal targets for the actions of NSAIDs. Rheum Dis Clin North Am 1998;24:501-23.
6. Gilkeson GS. Arachidonic acid derivatives, kinins, clotting factors, amines, nitric oxide and reactive oxygen species. In: Klippel JH, Weyand CM, Wortmann RL, editors. Primer on the rheumatic diseases, 11th ed. Atlanta: Arthritis Foundation; 1997. p. 58-63.
7. Salvati P, Lamberti E, Ferrario R, Ferrario RG, Scampini G, Pugliese F, et al. Long term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. Kidney Int 1995;47:1168-75.
8. Rosen GD, Birkenmeier TM, Raz A, Holtzman MJ. Identification of cyclooxygenase-related gene and its potential role in prostaglandin formation. Biochem Biophys Res Commun 1989;164:1358-65.
9. Robinson DR. Eicosanoids and related compounds. In: Koopman WJ, editor. Arthritis and allied conditions. 13th ed. Baltimore: Williams & Wilkins; 1997. p. 515-28.
10. Jouzeau JY, Terlain B, Abid A, Nedelac E, Netter P. Cyclo-oxgenase isoenzymes. Drugs 1997;53:563-82.
11. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997;24 Suppl 49:6-8.
12. Bolten WW. Scientific rationale for specific inhibition of COX-2. J Rheumatol 1998;25 Suppl 51:2-7.
13. DeWitt DL, Meade EA. Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isoenzymes. Arch Biochem Biophys 1993; 306:94-102.
14. Ristimiki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 1996;318:323-31.
15. Hoff T, DeWitt DL, Kaever V, Resch K, Goppelt-Struebe M. Differentiation-associated expression of prostaglandin G/H synthase in monocytic cells. FEBS Lett 1993;320:38-42.
16. Crofford LJ, Wilder RL, Ritmaski AP, Hajime S, Remmers EF, Epps HR. Cyclooxygenase-1 and -2 expressions in rheumatoid synovial tissues: effects of interleukin-1β, phorbol ester and corticosteroids. J Clin Invest 1994;93:1095-101.
17. Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Maciag T, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 1992;89:97-108.
18. Pablos JS, Santiago B, Carreira PE, Galindo M, Gomez-Reino JJ. Cyclooxygenase 1 and 2 expression by rheumatoid synovial fluid T cells [abstract]. Arthritis Rheum 1998;41 Suppl 9:S321.
19. Yagamata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993;11: 371-86.
20. Kaufman WE, Andreasson KI, Isakson PC, Worley PF. Cyclooxygenases and the central nervous system. Prostaglandins 1997;54:601-24.
21. Harris RC, McKanna JA, Akai Y, Jacobson HR, DuBois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-10.
22. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 1998; 274:R263-79.
23. Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997;272:F460-8.
24. Malmberg AB, Yaksh TL. Anti-nociceptive actions of spinal non-steroidal anti-inflammatory agents on the formalin test in the rat. J Pharmacol Exp Ther 1992; 263:136-45.
25. Willingale HL, Gardiner NJ, McLymont N, Giblett S, Grubb BD. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol 1997;122:1593-604.
26. Hay C, de Balleroche J. Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord. Neuroreport 1997;8: 1249-51.
27. Smith WL, Meade EA, DeWitt DL. Interactions of PGH synthase isoenzymes-1 and -2 with NSAIDs. Ann N Y Acad Sci 1994;744:50-7.
28. Ando M, Kol S, Kokia E, Ruutiainen-Altman K, Sirois J, Rohan RM, et al. Rat ovarian prostaglandin endoperoxide synthase-1 and -2: peri-ovulatory expression of granulosa cell-based interleukin-1-dependent enzymes. Endocrinology 1998;139:2501-8.
29. Simon LS. Biological effects of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1997;9:178-82.
30. Lim H, Paria BC, Das SK, Dinchuk JE, Langebach R, Trzaskos JM, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91:197-208.
31. Charpigny G, Reinaud P, Tamby JP, Creminon C, Guillomot M. Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in ovine embryos during implantation period. Biol Reprod 1997;57:1032-40,
32. Maciel FMB, Serrazin P, Morisset S, Lora M, Patry C, Dumais R, et al. Induction of cyclooxygenase-2 by parathyroid hormone in human osteoblasts in culture. J Rheumatol 1997;24:2429-35.
33. Tetradis S, Pilbeam CC, Liu Y, Herschman HR, Kream BE. Parathyroid hormone increases prostaglandin G/H synthase-2 transcription by a cyclic adenosine 3′,5′-monophosphate-mediated pathway in murine osteoblastic MC3T3-E1 cells. Endocrinology 1997; 138:3594-600.
34. Kraemer SA, Meade SA, DeWitt DL. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys 1992;293: 391-400.
35. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992;267:4338-44.
36. Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol 1997;24 Suppl 49:15-9.
37. Simon LS. Biology and toxic effects of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1998; 10:153-8.
38. Morita I, Schindler M, Regier MK, Otto JC, Hod T, DeWitt DL, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995;270:10902-8.
39. Amin A, Attur M, Dave M, Abramson S. Localization and regulation of COX-2 by nitric oxide in activated murine macrophages [abstract]. Arthritis Rheum 1998;41 Suppl 9:S143.
40. Reddy ST, Herschman HR. Ligand-induced prostaglandin synthesis requires expression of the TIS10/ PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages. J Biol Chem 1994;269: 15473-80.
41. 2 in mouse bone marrow-derived mast cells. J Biol Chem 1994;269:22269-75.
42. Langebach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et al. Prostaglandin synthase-1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-92.
43. 2 biosynthesis in cyclooxygenase 1 or 2 null cells. J Exp Med 1998;187:517-23.
44. Morham SG, Langebach R, Loftin CD, Tiano HF, Vouloumanos N, Jeanette C, et al. Prostaglandin synthase-2 gene disruption caused severe renal pathology in the mouse. Cell 1995;83:473-82.
45. Rome LH, Lands WEH. Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci U S A 1975;72:4863-5.
46. Kulmacz RJ, Lands WEM. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem 1985;260: 12572-8.
47. Quellet M, Percival MD. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 1995;306:247-51.
48. Laneuville O, Breuer DK, DeWitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994;271:927-34.
49. Copeland RA, William JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible form of prostaglandin G/H synthase. Proc Natl Acad Sci U S A 1994;91:11202-6.
50. Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneimittel Forschung 1995;45:1096-8.
51. Lecomte M, Laneuville O, Ji C, DeWitt DL, Smith WL. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994;269:13207-15.
52. Mancini JA, O'Neill GP, Bayly C, Vickers PJ. Mutation of serine 516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis. FEES Lett 1994;342:33-7.
53. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998;104 Suppl 3A:23S-9S.
54. Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. J Rheumatol 1998;25 Suppl 51:8-16.
55. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993;88:1318-23.
56. Gabriel SE, Jaakkimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis Rheum 1993;36:447-59.
57. Silverstein FE, Graham DY, Senior JR, Davies HW, Strainers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123: 241-9.
58. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18 Suppl 28:6-10.
59. Fries JF. NSAID gastropathy: epidemiology. J Musculoskel Med 1991;8:21-8.
60. Schoen RT, Vender RJ. Mechanisms of nonsteroidal antiinflammatory drug-induced gastric damage. Am J Med 1989;86:449-58.
61. Price AH, Fletcher M. Mechanisms of NSAID-induced gastroenteropathy. Drugs 1990;40 Suppl 5:1-11.
62. Lichtenberger LM, Graziani LA, Dial EJ, Butler BD, Hills BA. Role of surface active phospholipids in gastric cytoprotection. Science 1993;219:1327-9.
63. Lichtenberger LM, Wang ZM, Romero JJ, Ulloa C, Perez JC, Giraud MN, et al. Non-steroidal antiinflammatory drugs (NSAIDs) associated with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nat Med 1995;1:154-8.
64. Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995;30: 289-99.
65. Mahmud T. Scott DL, Bjarnason I. A unifying hypothesis for the medication of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996;55:211-3.
66. Lipsky PE, Isakson PC. Outcome of specific COX-2 inhibition in rheumatoid arthritis. 1 Rheumatol 1997;24 Suppl 49:9-14.
67. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic diseases: implications of nonsteroidal antiinflammatory drug therapy. Semin Arthritis Rheum 1996;26: 436-47.
68. Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med Res Rev 1996;16:181-206.
69. Fenner H. Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles. Semin Arthritis Rheum 1997;26 Suppl 1:28-33.
70. De Brum-Fernandes AJ. New perspectives for nonsteroidal antiinflammatory therapy. J Rheumatol 1997; 24:246-8.
71. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: the double-edged sword. Arthritis Rheum 1995;38:5-18.
72. Hawkey CJ, Karrasch JA, Szczepanski L. Walker DG, Barkun A. Swannell AJ, et al, for the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34.
73. Yeomans ND, Tulassay Z, Juhász L, Rácz I, Howard JM, van Rensburg CJ, et al, for the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719-26.
74. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 1996;334: 1435-9.
75. Blanchi Porro G, Parrente F, Imbesi V, Montrons F, Caruso I. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users: response to omeprazole dual therapy. Gut 1996;36:22-6.
76. Hawkey CJ, Tulassay Z, Szczepanski L, van Renburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet 1998;352:1016-21.
77. Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroiclal antiinflammatory drugs. Arthritis Rheum 1998;41:16-25.
78. Roth SH. Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. Am J Med 1987;83:25-30.
79. Lanza F, Rack MF, Lynn M, Wolf J, Sanda M. An endoscopic comparison of the effects of etodolac, indomethacin, ibuprofen, naproxen, and placebo on the gastrointestinal mucosa. J Rheumatol 1987;14: 338-41.
80. Willkins RF. An overview of the long-term safety experience of nabumetone. Drugs 1990;40 Suppl 5:34-7.
81. Levitt B, Chapelsky M, Boyle G, Wells T, Jones S, Jorkasky D. Safety and pharmacokinetics of nabumetone and 6-MNA in juvenile rheumatoid arthritis patients and healthy adult males following repeated oral doses of nabumetone chewable tablets [abstract]. Arthritis Rheum 1998;41 Suppl 9:S46.
82. Dandona P, Jerenny JY. Nonsteroidal anti-inflammatory drug therapy and gastric side effects: does nabumetone provide a solution? Drugs 1990;40 Suppl 5:16-24.
83. Blower PR. The unique pharmacologic profile of nabumetone. J Rheumatol 1992;19 Suppl 36:13-9.
84. Singh G, Terry R. Ramey DR, Fries JF, Triadafilopoulos G, Halpern J, et al. Comparative GI toxicity of NSAIDs [abstract]. Arthritis Rheum 1997;40 Suppl 9:S115.
85. Glaser K. Sung M-L, O'Neill K, Belfast M, Hartman D, Carlson R, et al. Etodolac selectivity inhibits human prostaglandin G/H synthase (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995;281:107-11.
86. Schattenkirchner M. An update safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 1990;10:56-65.
87. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum 1997;26 Suppl 1:21-7.
88. Lanza F, Panagides J, Salom IL. Etodolac compared with aspirin: an endoscopic study of the gastrointestinal tracts of normal volunteers. J Rheumatol 1986; 13:299-303.
89. Bocanegra TS, Kivitz A, Hurley SM, Talwalker S, Ball JA, Kuss ME, et al. Treatment of osteoarthritis with diclofenac/misoprostol is associated with a lower incidence of gastroduodenal ulcers compared to nabumetone and naproxen [abstract]. Arthritis Rheum 1998;41 Suppl 9:S197.
90. Marini U, Spotti D. Gastric tolerability of nimesulide: a double-blind comparison of 2 oral dosage regimens and placebo. Drugs 1993;46 Suppl 1:249-52.
91. Patoia L, Santucci L, Furno P, Dionisi MS, Dell'Orso S, Romagnoli M, et al. A 4-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996;35 Suppl 1:61-7.
92. Drieser RL, Benvelli DC. Long-term tolerability profile of nimesulide in the treatment of osteoarthritis. Drugs 1993;46 Suppl 1:270-4.
93. Wojtulewski JA, Schattenkirchner M, Barcelo P, Le Laet X, Bevis PJ, Bluhmki E, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996;35 Suppl 1:22-8.
94. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996;35 Suppl 1:39-43.
95. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996;35 Suppl 1:35-8.
96. Davis R, Brogden RN. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994;48:431-54.
97. Distel M. Mueller C, Bluhmki E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology 1996;4:71-8.
98. Barrier A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996;25 Suppl 102:29-37.
99. Geis GS, Stead H, Morant S, Naudin R, Hubbard R. Efficacy and safety of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1998;41 Suppl 9:S316.
100. Geis GS, Hubbard R, Callison D, Yu S, Zhao W. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1998;41 Suppl 9:S364.
101. Hubbard R, Geis GS, Woods E, Yu S, Zhao W. Efficacy, tolerability and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis [abstract]. Arthritis Rheum 1998;41 Suppl 9:S196.
102. Cannon G, Caldwell J, Holt P, McLean B, Zeng Q, Ehrich E, et al, for the MK-0966 Phase III Protocol 035 Study Group. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis in a 26-week controlled clinical trial [abstract]. Arthritis Rheum 1998;41 Suppl 9:S196.
103. Saag K, Fisher C, McKay J, Ehrich E, Zhao P-L, Bolognese J, et al, for the MK-0966 Phase III Protocol 033 Study Group. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis in a 6-week controlled clinical trial [abstract]. Arthritis Rheum 1998;41 Suppl 9:S196.
104. Ehrich E, Bolognese J, Kong S, Watson DJ, Zeng Q, Seidenberg B. Improvements in SF-36 mental health domains with treatment of OA: a result of decreased pain and disability or independent mechanisms [abstract]? Arthritis Rheum 1998;41 Suppl 9:S221.
105. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996;97:2672-9.
106. Masferrer JL, Sweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci U S A 1994;91:3228-32.
107. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebocontrolled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
108. Lanza FL, Callison DA, Hubbard RC, Yu SS, Tawalker S, Geis GS. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a COX-2-selective inhibitor [abstract]. Arthritis Rheum 1997;40 Suppl 9:S93.
109. Hubbard RC, Koepp R, Yu SS, Talwalker S, Geis GS. Pilot efficacy of SC-58635, a COX-2-selective inhibitor, in rheumatoid arthritis [abstract]. Arthritis Rheum 1997;40 Suppl 9:S51.
110. Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol 1997;24 Suppl 49: 20-4.
111. Mengle-Gaw L, Hubbard RC, Karim A, Yu SS, Tawalker S, Isakson PC, et al. A study of the platelet effects of SC-58635, a novel COX-2-selective inhibitor [abstract]. Arthritis Rheum 1997;40 Suppl 9:S93.
112. Karim A, Tolbert D, Piergies A, Hunt T, Hubbard R, Harper K, et al. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin [abstract]. Arthritis Rheum 1998;41 Suppl 9:S315.
113. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Aci U S A 1999;96:272-7.
114. Ehrich E, Schnitzer T, Kivitz A, Weaver A, Wolfe F, Morrison B, et al, for the MK-966 Osteoarthritis Phase II Study Group. MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study [abstract]. Arthritis Rheum 1997;40 Suppl 9:S85.
115. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Nogichi H, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-97.
116. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
117. O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD. Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 1996;66: 2532-40.
118. Pasinetti GM. Inflammatory mechanisms in neurode-generation and Alzheimer's disease: the role of the complement system. Neurobiol Aging 1996;17:707-16.
119. Lukiw WJ, Bazan NG. Cyclo-oxygenase-2 RNA message abundance, stability and hypervariability in sporadic Alzheimer neocortex. J Neurosci Res 1997; 50:937-45.
120. Stewart WF, Kawas C, Carrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997;48:626-32.
121. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1-19.
122. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
123. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618-9.
124. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990;50:2562-8.
125. Craven PA, DeRubertis FR. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis 1992;13:541-6.
126. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol 1988;156:341-7.
127. Eberhart CE, Coffrey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-8.
128. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94:3336-40.
129. Zhang F, Subbaramaiah K, Altorki N, Dannenberg AJ. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J Biol Chem 1998;273:2424-8.
130. Bennett A, Charlier EM, McDonald AM, Simpson MS, Stamford IF, Zebro T. Prostaglandins and breast cancer. Lancet 1997;2:624-6.
131. Jung TTK, Berlinger NT, Juhn SK. Prostaglandins in squamous cell carcinoma of the head and neck: a preliminary study. Laryngoscope 1985;95:307-12.
132. Nakatsugi S, Fukutake M, Takahashi M, Fukuda K, Isoi T, Taniguchi Y, et al. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn Cancer Res 1997;88:1117-20.
133. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87: 803-9.
134. Lipsky PE. Cyclo-oxygenase research: advances with clinical implications. In: Emery P, editor. Fast facts-rheumatology highlights 1997. Oxford: Health Press; 1998. p. 24-30.